(IBBQ) Invesco Nasdaq Biotechnology - Ratings and Ratios
Biotechnology, Pharmaceutical, Nasdaq, Securities, Non-Diversified
Dividends
| Dividend Yield | 0.81% |
| Yield on Cost 5y | 0.92% |
| Yield CAGR 5y | 18.46% |
| Payout Consistency | 100.0% |
| Payout Ratio | - |
| Risk via 5d forecast | |
|---|---|
| Volatility | 17.5% |
| Value at Risk 5%th | 29.6% |
| Relative Tail Risk | 3.14% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.00 |
| Alpha | 18.19 |
| CAGR/Max DD | 0.45 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.457 |
| Beta | 0.701 |
| Beta Downside | 0.641 |
| Drawdowns 3y | |
|---|---|
| Max DD | 23.66% |
| Mean DD | 6.02% |
| Median DD | 4.97% |
Description: IBBQ Invesco Nasdaq Biotechnology November 03, 2025
The Invesco Nasdaq Biotechnology ETF (IBBQ) aims to track a Nasdaq-compiled index that is weighted by modified market capitalization and includes biotech and pharmaceutical firms of all sizes listed on the Nasdaq. By mandate, at least 90 % of the fund’s assets must be invested in the index constituents, making it a non-diversified vehicle focused on the health-care sector.
Key quantitative points to consider (as of the latest public filings) include an expense ratio of roughly 0.39 % and total assets under management near US $250 million, indicating modest scale relative to broader health-care ETFs. The biotech sector’s growth is heavily driven by FDA approval cycles and R&D spending, with the U.S. biotech market projected to expand at a CAGR of ~10 % through 2028, which can amplify both the upside and volatility of IBBQ’s holdings.
If you want to see how IBBQ’s exposure stacks up against alternative biotech strategies and assess its risk-adjusted performance, ValueRay’s analytical platform offers a convenient way to compare metrics and scenario analyses.
What is the price of IBBQ shares?
Over the past week, the price has changed by -0.61%, over one month by +1.41%, over three months by +19.15% and over the past year by +26.47%.
Is IBBQ a buy, sell or hold?
What are the forecasts/targets for the IBBQ price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 30 | 6.5% |
IBBQ Fundamental Data Overview December 17, 2025
Beta = 0.84
Revenue TTM = 0.0 USD
EBIT TTM = 0.0 USD
EBITDA TTM = 0.0 USD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = unknown
Enterprise Value = 58.9m USD (58.9m + (null Debt) - (null CCE))
Interest Coverage Ratio = unknown (Ebit TTM 0.0 / Interest Expense TTM 0.0)
FCF Yield = 0.0% (FCF TTM 0.0 / Enterprise Value 58.9m)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = unknown (Enterprise Value 58.9m / Total Assets none)
Interest Expense / Debt = unknown (Interest Expense 0.0 / Debt none)
Taxrate = 21.0% (US default 21%)
NOPAT = 0.0 (EBIT 0.0 * (1 - 21.00%))
Current Ratio = unknown (Total Current Assets none / Total Current Liabilities none)
Debt / Equity = unknown (Debt none)
Debt / EBITDA = unknown (Net Debt none / EBITDA 0.0)
Debt / FCF = unknown (Net Debt none / FCF TTM 0.0)
Total Stockholder Equity = 0.0 (from calculated bookValueOfEquity)
RoA = unknown (Net Income 0.0 / Total Assets none)
RoE = unknown (Net Income TTM 0.0 / Total Stockholder Equity 0.0)
RoCE = unknown (EBIT 0.0 / Capital Employed )
RoIC = unknown (NOPAT 0.0, Invested Capital 0.0, EBIT 0.0)
WACC = 8.60% (E(58.9m)/V(58.9m) * Re(8.60%) + (debt-free company))
Discount Rate = 8.60% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow 0.0)
Additional Sources for IBBQ ETF
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle